BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
Izotropic Corporation (OTCQB: IZOZF) has launched BreastCT.com, a comprehensive educational platform focused on breast CT technology and the company's IzoView Breast CT Imaging System. The website aims to educate about dedicated breast CT technology, particularly highlighting its potential in addressing breast cancer detection challenges for the 50% of women with dense breast tissue.
With IzoView's engineering phase now complete, the platform will evolve through clinical studies, regulatory phases, and commercial launch preparations. The site also contextualizes Izotropic's position by featuring successful public companies that have established new imaging categories, helping build market recognition ahead of future milestones.
Izotropic Corporation (OTCQB: IZOZF) ha lanciato BreastCT.com, una piattaforma formativa completa dedicata alla tecnologia di tomografia mammaria e al sistema IzoView Breast CT Imaging System dell'azienda. Il sito è pensato per informare sulla tomografia mammaria specifica, mettendo in evidenza il suo potenziale nel migliorare la rilevazione del cancro al seno, specialmente per la metà delle donne con tessuto mammario denso.
Ora che la fase di ingegneria di IzoView è conclusa, la piattaforma si svilupperà attraverso studi clinici, iter regolatori e preparativi per il lancio commerciale. Il sito inquadra inoltre la posizione di Izotropic mostrando esempi di società quotate che hanno creato nuove categorie di imaging, contribuendo a costruire riconoscimento sul mercato in vista dei prossimi traguardi.
Izotropic Corporation (OTCQB: IZOZF) ha lanzado BreastCT.com, una plataforma educativa integral centrada en la tomografía de mama y en el IzoView Breast CT Imaging System de la compañía. El objetivo del sitio es informar sobre la tecnología de TC mamaria dedicada, subrayando su potencial para afrontar los retos de detección del cáncer de mama, especialmente en el 50% de las mujeres con tejido mamario denso.
Con la fase de ingeniería de IzoView ya completada, la plataforma evolucionará a través de estudios clínicos, procesos regulatorios y preparativos para el lanzamiento comercial. Además, la web sitúa a Izotropic en contexto mostrando empresas cotizadas que han creado nuevas categorías de imagen, ayudando a generar reconocimiento de mercado antes de futuros hitos.
Izotropic Corporation (OTCQB: IZOZF)는 유방 CT 기술과 자사 IzoView Breast CT Imaging System에 관한 종합 교육 플랫폼 BreastCT.com을 공개했습니다. 이 사이트는 전용 유방 CT 기술을 소개하며, 특히 유방 밀도가 높은 여성의 약 50%에서 유방암 검출 문제를 해결할 수 있는 잠재력을 강조합니다.
IzoView의 엔지니어링 단계가 완료됨에 따라 플랫폼은 임상 연구, 규제 절차, 상업 출시 준비 과정을 거치며 발전할 예정입니다. 또한 성공적인 상장 기업들이 새 영상 분야를 개척한 사례를 소개해 Izotropic의 시장 인지도를 향후 주요 이정표 전에 구축하는 데 도움을 주고 있습니다.
Izotropic Corporation (OTCQB: IZOZF) a lancé BreastCT.com, une plateforme éducative complète dédiée à la technologie de tomodensitométrie mammaire et au IzoView Breast CT Imaging System de la société. Le site vise à informer sur la tomographie mammaire dédiée, en soulignant son potentiel pour améliorer la détection du cancer du sein, notamment pour les 50 % des femmes présentant un tissu mammaire dense.
La phase d'ingénierie d'IzoView étant désormais achevée, la plateforme évoluera au fil des études cliniques, des étapes réglementaires et des préparatifs du lancement commercial. Le site replace également Izotropic dans son contexte en présentant des entreprises cotées ayant créé de nouvelles catégories d'imagerie, contribuant à renforcer la notoriété sur le marché en vue des prochaines étapes.
Izotropic Corporation (OTCQB: IZOZF) hat BreastCT.com gestartet, eine umfassende Bildungsplattform zur Brust-CT-Technologie und zum IzoView Breast CT Imaging System des Unternehmens. Die Website soll über dedizierte Brust-CT-Technik aufklären und betont insbesondere deren Potenzial zur Verbesserung der Brustkrebsdetektion bei den 50 % der Frauen mit dichtem Brustgewebe.
Da die Ingenieursphase von IzoView nun abgeschlossen ist, wird sich die Plattform über klinische Studien, regulatorische Schritte und Vorbereitungen für die Markteinführung weiterentwickeln. Die Seite ordnet Izotropic zudem ein, indem sie erfolgreiche börsennotierte Unternehmen zeigt, die neue Bildgebungskategorien etabliert haben, um die Marktbekanntheit vor künftigen Meilensteinen zu steigern.
- Engineering phase of IzoView Breast CT Imaging System is complete
- Platform targets large market opportunity with 50% of women having dense breast tissue
- Strategic positioning alongside successful imaging companies for market recognition
- Product still requires clinical studies and regulatory approvals before commercialization
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company’s awareness initiatives.
BreastCT.com has been created as a central educational resource on dedicated breast CT technology and the Company’s IzoView Breast CT Imaging System, with a focus on its potential to address persistent challenges in detecting breast cancer in the
This new content positions Izotropic within a broader industry context by highlighting public companies that have successfully created and led new imaging categories. This approach gives audiences a clear frame of reference for where IzoView Breast CT could fit within an evolving market to build recognition ahead of future regulatory and commercial milestones.
At strategic times, Izotropic will integrate native advertising campaigns into BreastCT.com to help drive awareness in alignment with the Company’s goals.
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the purpose of Izotropic's new BreastCT.com website?
What stage is Izotropic's (IZOZF) IzoView Breast CT System in development?
How many women could benefit from Izotropic's (IZOZF) breast CT technology?
What is Izotropic's (IZOZF) marketing strategy for BreastCT.com?
